Pfizer is currently embroiled in multiple legal battles concerning its recent recall of the sickle-cell medication, Oxbryta. The lawsuits hinge on accusations that Pfizer failed to update the drug’s labels with new scientific information, a requirement under federal law. The plaintiff’s complaint specifically states, “Federal law requires defendants to ensure that their drug labels remain accurate, and when new scientific information renders their labels inaccurate, federal law requires defendants to act.” The failure to update these labels has led to claims that the medication is now misbranded. The unfolding legal scenario brings significant attention to the stringent requirements pharmaceutical companies face regarding drug labeling and regulatory compliance.
For more information, the original article and complaints about ensuring the accuracy of drug labels with updated scientific data can be read [here](https://www.feedblitz.com/fake/).